EnVVeno Medical Corporation
NVNO
株式のランク
#40245
enVVeno Medical Corporation, based in Irvine, California, is a medical device... enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
株価
$10.71
最終同期: 2026-07-31
時価総額
$176.75K
変化（1日）
0.79%
変化（1年）
169,900.00%
国
US
取引 EnVVeno Medical Corporation (NVNO)
カテゴリー
Healthcare
EnVVeno Medical Corporation（NVNO）の営業利益率
2026 時点の営業利益率 TTM: 0.00%
EnVVeno Medical Corporation の最新の財務報告と株価によると、現在の営業利益率（TTM）は 0.00% です。2026 年末時点では 0.00% でした。
EnVVeno Medical Corporation の営業利益率の履歴（2026 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 17.03% | - |
US
|
|
| 17.86% | - |
IE
|
|
| 22.03% | - |
US
|
|
| 21.46% | - |
US
|
|
| 0.00% | - |
DE
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。